# Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Source: https://onco.cc/trials/nct06960577/  
OnCo record `nct06960577` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab, Methotrexate, Vinblastine, Doxorubicin, Cisplatin and Gemcitabine in bladder & urothelial cancer, run by AstraZeneca, now recruiting.

## Summary

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) is a phase 3 interventional study registered as NCT06960577 by AstraZeneca, with 150 participants planned, started 2025-05-15 and due to reach its primary completion in 2028-10-31. Interventions recorded: Durvalumab, Methotrexate, Vinblastine, Doxorubicin, Cisplatin and Gemcitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06960577
- Phase: 3
- Setting: A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
- Sponsor: AstraZeneca
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT06960577: https://clinicaltrials.gov/study/NCT06960577

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Methotrexate](https://onco.cc/drugs/methotrexate/), [Vinblastine](https://onco.cc/drugs/vinblastine/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06960577.json